![PDF) Real-world data on treatment outcomes in EGFR- mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines PDF) Real-world data on treatment outcomes in EGFR- mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines](https://i1.rgstatic.net/publication/351589639_Real-world_data_on_treatment_outcomes_in_EGFR-_mutant_non-small-cell_lung_cancer_patients_receiving_osimertinib_in_second_or_further_lines/links/61dfeee75c0a257a6fe6a02e/largepreview.png)
PDF) Real-world data on treatment outcomes in EGFR- mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines
A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation
![Cancers | Free Full-Text | The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study Cancers | Free Full-Text | The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study](https://www.mdpi.com/cancers/cancers-14-04835/article_deploy/html/images/cancers-14-04835-g001.png)
Cancers | Free Full-Text | The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study
![PDF) Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: A multicenter study PDF) Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: A multicenter study](https://i1.rgstatic.net/publication/315435545_Efficacy_and_safety_of_T-DM1_in_the_'common-practice'_of_HER2_advanced_breast_cancer_setting_A_multicenter_study/links/59032b65a6fdccd580cf2ad4/largepreview.png)
PDF) Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: A multicenter study
![A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study | British Journal of Cancer A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.bjc.6602241/MediaObjects/41416_2004_Article_BF6602241_Fig1_HTML.gif)
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study | British Journal of Cancer
![La REGINA d'ITALIA ELENA di MONTENEGRO, .....un busto in suo onore al Polo Oncologico di Roma - Consul Press La REGINA d'ITALIA ELENA di MONTENEGRO, .....un busto in suo onore al Polo Oncologico di Roma - Consul Press](https://www.consulpress.eu/wp-content/uploads/2023/01/1-IMG-20230108-WA0029.jpg)
La REGINA d'ITALIA ELENA di MONTENEGRO, .....un busto in suo onore al Polo Oncologico di Roma - Consul Press
EGFR Inhibition Abrogates Leiomyosarcoma Cell Chemoresistance through Inactivation of Survival Pathways and Impairment of CSC Po
![Frontiers | Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trial Frontiers | Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trial](https://www.frontiersin.org/files/Articles/925366/fonc-12-925366-HTML/image_m/fonc-12-925366-g001.jpg)
Frontiers | Effectiveness of a phone-based nurse monitoring assessment and intervention for chemotherapy-related toxicity: A randomized multicenter trial
![La REGINA d'ITALIA ELENA di MONTENEGRO, .....un busto in suo onore al Polo Oncologico di Roma - Consul Press La REGINA d'ITALIA ELENA di MONTENEGRO, .....un busto in suo onore al Polo Oncologico di Roma - Consul Press](https://www.consulpress.eu/wp-content/uploads/2023/01/4-IMG-20230108-WA0064.jpg)
La REGINA d'ITALIA ELENA di MONTENEGRO, .....un busto in suo onore al Polo Oncologico di Roma - Consul Press
![IRE, Tumore Polmone: scoperte le mutazioni che causano resistenza all'immunoterapia - Istituti Fisioterapici Ospitalieri - IFO IRE, Tumore Polmone: scoperte le mutazioni che causano resistenza all'immunoterapia - Istituti Fisioterapici Ospitalieri - IFO](https://cdn.ifo.it/wp-content/uploads/2020/09/Annals-Oncology-Tumore-Polmone.png)